Publicacións nas que colabora con Andres Iñiguez Romo (14)

2022

  1. Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design

    American Heart Journal, Vol. 246, pp. 32-43

  2. Continuous Medical Education of Scientific Societies in Spain: analysis of current situation and proposals for future

    Medicina Clinica, Vol. 159, Núm. 1, pp. 47-52

2021

  1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  2. Value of non-apical echocardiographic views in the up-grading of patients with aortic stenosis

    Scandinavian Cardiovascular Journal, Vol. 55, Núm. 5, pp. 279-286

2020

  1. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention

    European Heart Journal: Acute Cardiovascular Care, Vol. 9, Núm. 7, pp. 764-770

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 148-156

  3. Incidence, predictors and prognosis of new-onset cancer after hospital discharge for acute coronary syndrome

    REC: CardioClinics, Vol. 54, Núm. 3, pp. 148-156

  4. Renin–Angiotensin System Blockade and Risk of Heart Failure After Myocardial Infarction Based on Left Ventricular Ejection Fraction: A Retrospective Cohort Study

    American Journal of Cardiovascular Drugs, Vol. 19, Núm. 5, pp. 487-495

  5. Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor

    Thrombosis Research, Vol. 174, pp. 51-58

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2016

  1. NT-proBNP for risk stratification of nonagenarian patients with severe symptomatic aortic stenosis

    International Journal of Cardiology, Vol. 223, pp. 785-786

  2. On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013

    Revista Espanola de Cardiologia, Vol. 69, Núm. 6, pp. 551-553

2015

  1. Post-introduction observation of transcatheter aortic valve implantation in Galicia (Spain)

    Journal of Evaluation in Clinical Practice, Vol. 21, Núm. 1, pp. 34-42